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Abstract
Background: Adequate anticoagulation is prerequisite for effective hemodialysis to prevent clotting in the
extracorporeal circuit. We aimed providing first data on the efficacy and safety of the low-molecular-weight heparin
certoparin in this setting.
Methods: Multicenter, open-label, 8-week trial. Patients received a single dose of 3,000 IU certoparin i.v. with
additional titration steps of 600 IU and/or continuous infusion if necessary.
Results: 120 patients were screened, 109 enrolled (median age 71; range 26–90 years) and 106 available for efficacy
analyses. The percentage of unsatisfactory dialysis results at 8 weeks due to clotting or bleeding, was 1.9%
(n = 2/106; 95% confidence interval [CI] 0.23–6.65%); no major bleeding. 1.9% had moderate/severe clotting in the
lines/bubble catcher and 2.8% in the dialyser at week 8. 15.7 ± 14.3% of the dialysis filters’ visual surface area was
showing redness. In subgroups of patients receiving median doses of 3000 ± 0, 3000 (2400–6000) and 4200
(3000–6600) IU, plasma aXa levels at baseline, 4 and 8 weeks were 0.24 [95%CI 0.21–0.27], 0.33 [0.27–0.40] and 0.38
[0.33–0.45] aXa IU/ml at 2 h. C48h was 0.01 [0.01–0.02] aXa IU at all visits. At baseline and 4 weeks AUC0-48h was 2.66
[2.19–3.24] and 3.66 [3.00–4.45] aXa IU*h/ml. In 3.0% of dialyses (n = 83/2724) prolonged fistula compression times
were documented. Eight patients (7.34%) had at least one episode of minor bleeding. 4) 85.3% of patients had any
adverse event, 9.2% were serious without suspected drug relation; and in 32 patients a drug-relation was suspected.
Conclusions: Certoparin appears effective and safe for anticoagulation in patients undergoing maintenance
hemodialysis.
Background
Adequate anticoagulation is a precondition for effective
hemodialysis to prevent clotting in the extracorporeal
circuit and to improve biocompatibility of artificial
membranes [1]. For this purpose, unfractionated
heparin (UFH) is currently the most widely used anti-
coagulant [1,2]. However, low molecular weight hepar-
ins (LMWH) have the advantage over UFH in that they
show less nonspecific binding to endothelium, macro-
phages, platelets and plasma proteins, a more predict-
able anticoagulant response, and usually have a low
requirement for monitoring [3]. Furthermore, chronic
UFH use may cause a number of untoward effects,
such as heparin induced dyslipidemia [4,5], an
increased risk of bleeding [6,7], allergic reactions [8],
thrombocytopenia [9], osteoporosis [10] and aldoster-
one suppression [11].
Certoparin was shown to be safe and effective in
patients with chronic renal insufficiency in a recent sub-
group analysis of the CERTIFY study [12]. Its action may
be partially reversed by protamine hydrochloride [13].
Compared to other LMWHs certoparin has an inter-
mediate renal clearance of antiXa activity (3.6-4.1%)
[14,15] and body weight independent dosing [16]. The
present feasibility trial was designed to provide data on
the efficacy and safety of certoparin in the prophylaxis of
clotting in the extracorporeal circuit in patients receiving
routine hemodialysis 2-3 times per week.
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Methods
MEMBRANE was a multicenter, open-label, non-con-
trolled prospective in patients undergoing maintenance
hemodialysis (ClinicalTrials.gov Identifier: NCT01179620).
The study was conducted between July 2010 (first patient
in) and March 2011 (last patient out) in accordance with the
ethical principles of the Declaration of Helsinki. It was re-
viewed by the Independent Ethics Committee or Institu-
tional Review Board for each participating centre. These
included the General Medical Council (Landesärztekammer)
in Munich, Frankfurt, Dresden, Bad Segeberg and Münster
and the ethic committees of the Technical University
Munich, the University of Münster and the University of
Magdeburg. Informed consent was obtained from each
subject in writing.
The protocol was amended once after the inclusion of
12 patients which introduced the allowance for an infusion
of certoparin in case the chosen bolus was not sufficient,
added a second pharmacokinetic analysis, and increased
the sample size to adjust for the additional inclusion of
patients with hemofiltration (HF) and hemodiafiltration
(HDF) (for details see the respective paragraphs).
Principal study design
Studies investigating the efficacy and safety of LMWH
for anticoagulation during chronic hemodialysis have
used a variety of designs [17] and there is no guidance
from the European Medicines Agency (EMA) for setting
up such a study. In the 17 randomized, controlled trials
which were included in the systematic review of Lim
et al. [17], 10 used a randomized open cross-over design,
one a blinded cross-over design, and 6 were open trials
using a parallel design. Studies ranged in size and dur-
ation from 8 to 149 patients and 1 session up to
36 months, respectively. In none of the trials using a
parallel control arm, a predefined comparative statistical
hypothesis was tested.
Outcomes compared in the systematic review by Lim
[17] were bleedings as a parameter determining the
safety of the interventions (assessed in 12 studies as
bleeding symptoms or access compression times),
thrombosis of the extracorporeal circuit as a parameter
determining efficacy (assessed in 17 studies) and anti-Xa
levels to establish pharmacokinetics (measured in 14
studies). Extracorporeal thrombosis was assessed by vis-
ual inspection or scoring of the extent of clotting in the
filter system, the lines and bubble catcher or the dialyzer
which in all cases was based on the subjective decision
of the investigators. One study rated the dialysis result
as satisfactory or unsatisfactory according to the scores
of the line/bubble catcher and the dialyzer.
During the design of the study we considered a con-
trolled setting with prospective hypothesis testing. For
this purpose a placebo-controlled design was not
considered adequate because prophylaxis of extracorpor-
eal clotting is widely considered necessary and a
standard procedure. For a UFH-controlled design we
expected no superiority of certoparin over UFH based
on the analysis of Lim [17]. On the other hand a non-
inferiority design was not deemed feasible because nei-
ther blinding and bias-free assessment nor sensitivity
and validation were appropriately achievable.
Therefore it appeared reasonable to aim at determin-
ing the proportion of patients with complications during
dialysis defined as the presence of clotting or major
bleeding using a straightforward, non-controlled design.
The assumption was that between 0 and 5% of patients
would experience adverse effects at week 8 and patient
numbers to verify this were adjusted to comply with
this objective. To show this clinical endpoint, no
randomization or comparator arm was needed.
Objectives
The primary objective of MEMBRANE was to investi-
gate the efficacy and safety of certoparin to prevent clot-
ting in the extracorporeal circuit during hemodialysis at
week 8. Therefore, the primary endpoint was defined as
the percentage of unsatisfactory dialysis results at week
8 due to clotting or bleeding. The dialysis was consid-
ered unsatisfactory if a score of 2 (moderate clotting) or
3 (severe clotting) was given to the lines/bubble catcher
(vs 0 for no clots and 1 for minimal clots) and/or the
dialyser (moderate redness overall or several ≥ 3) small
or few large (≥ 2 mm) dark red fibre bundles OR total
clotting of the dialyser defined as stop in hemodialysis
requiring change of the extracorporeal circuit) or if
any clotting required premature interruption of the
hemodialysis session (Table 1). Bleeding was considered
a reason for unsatisfactory dialysis when leading to pre-
mature interruption of the hemodialysis session or in
case of major bleeding.
Table 1 Criteria for the evaluation of clinical efficacy of
clotting prevention as evaluated visually by the
investigator at the study site at the end of the
hemodialysis after the first session and after week 8
Score Lines and bubble
catcher
Dialyser
Satisfactory 0 No clots Good, clear dialyser
1 Minimal clots Light redness overall or only a
few (< 3) and small (< 2 mm)
dark red fibre bundles
Unstatisfactory 2 Moderate clotting Moderate redness overall or
several (≥ 3) small or few large
(≥ 2 mm) dark red fibre bundles
3 Severe clotting Total clotting of the dialyser
(stop in hemodialysis, requiring
change of the extracorporeal
circuit).
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The secondary objectives were: 1) To assess the
pharmacokinetics of certoparin in subjects receiving
regular hemodialysis treatments including hemodiafiltra-
tion and hemofiltration, indirectly determined by the
concentration-time profile of antifactor Xa activity using
a chromogenic assay; 2) to document the safety and tol-
erability of certoparin over 8 weeks in subjects receiving
regular hemodialysis treatments; 3) to assess clinical effi-
cacy by inspection of the filter system (lines, bubble
catcher, dialyzer) at the site of dialysis by the staff in the
dialysis center; 4) To assess efficacy via the percentage of
clotted area in the transversal (= horizontal) plane of the
filter (at central lab). Safety endpoints were 1) antiXa ac-
tivity at the beginning and at the end of the hemodialysis
session at week 4 and week 8; 2) clinical and laboratory
factors that predict an excessive (anti-) coagulant effect
(anti-Xa, D-Dimer); and 3) bleeding events. Adverse
events were adjudicated by the local physician respon-
sible for the conduct of the study.
Further to these objectives cases of prolonged shunt
compression times were recorded. Normal shunt com-
pression times were 5 to 13 minutes in prior studies as
suggested by the meta-analysis by Lim [17]. The degree
of “prolongation” was not predefined however because
of the high clinical variability and left up to the treating
physician. In the amendment exploratory objectives were
added to assess the course of dose adaption and the out-
come of dialysis over time.
Patients
The patient population consisted of clinically stable am-
bulatory patients of at least 18 years with established
chronic kidney disease (CKD) stage 5 D requiring
chronic hemodialysis (2-3 times per week) of at least 4 h
duration per session for at least 3 months. Hemoglobin
had to be ≥ 10.0 g/dL at the first visit. It is allowed to ad-
minister aspirin (repetitive dosing ≤ 325 mg daily, single
dosing of < 1000 mg), ticlopidine, clopidogrel, dipyrid-
amole or their combination. Selected exclusion criteria
were: 1) History of clinically significant bleeding within
the last 4 weeks; 2) Any acute or chronic illness interfer-
ing with coagulation; 3) History of heparin induced
thrombocytopenia type II (HIT II); 4) Target blood flow
during dialysis of less than 200 ml/min; 5) any concomi-
tant medication with dextran 40, chronic systemic gluco-
corticoids (≥ 4 months), thrombolytic agents and
anticoagulants (e.g. phenprocoumon) or glycoprotein
IIb/IIIa antagonists; 6) Acute or history of non-
hemorrhagic stroke (< 3 months); hemorrhagic stroke or
intracranial bleeding (< 12 months) or stroke for which
thrombolytic therapy was planned. After the amendment
the physicians were allowed to also include patients with
hemofiltration (HF) and hemodialfiltration (HDF).
Use and dosing of certoparin
Patients, before being connected for dialysis, received a
single bolus dose of 3,000 IU certoparin sodium i.v.
(Mono-EmbolexW; Novartis Pharma GmbH, Germany)
via the needle or the catheter but not into the arterial
line at 2-3 routinely scheduled hemodialysis sessions per
week for a total of 8 weeks. Titration was allowed in
dose steps of 600 IU up to a maximum dose of 6,000 IU.
These dose adjustments were made at the discretion of
the treating physician but not based on routine anti-
factor Xa determinations. The dialyser and blood lines
were not pre-rinsed with certoparin but only saline be-
fore dialysis.
Because of the fast elimination of certoparin documen-
ted in the pharmacokinetic analysis A (PK-A, see below),
the titration algorithm was changed with the amend-
ment, allowing to increase the bolus dose to a maximum
of 4,200 IU. If a satisfactory result was not achieved,
patients received a bolus of 3,000 IU plus an infusion of
600 IU/h up to 1 h before the end of the dialysis session.
This would result in a total dose of 4,800 IU for patients
who were dialyzed for 4 h. If a satisfactory result was
still not achieved the bolus was increased stepwise
(3,600 IU and 4,200 IU) combined with an infusion of
600 IU/h resulting in cumulative doses of up to
6,600 IU. After completion of dose adaption, the indi-
vidually titrated certoparin dose was to be used in subse-
quent dialyses.
Definition of bleeding complications
Bleeding complications were assessed by the local phys-
ician in charge for the study. Major bleeding was defined
as fatal bleeding, clinically overt bleeding associated with
a fall of the haemoglobin concentration greater than
20 g/l compared to baseline, clinically overt bleeding
that requires transfusion of two or more units of packed
red cells or whole blood, symptomatic bleeding in a crit-
ical area or organ, such as intracranial, intraspinal, retro-
peritoneal, pericardial bleeding. Minor bleeding was
defined as bleeding events which do not meet the above
mentioned criteria. Arteriovenous fistula bleeding was
recorded when compression time at the end of the dialy-
sis session was prolonged and was recorded separately.
Pharmacodynamic assessment
In a subgroup of 12 patients in 3 selected centers (re-
ferred to as PK-A) blood samples were collected from
fistula prior to the dialysis according to a predetermined
schedule at the first dialysis session, and at a session
after 4 weeks (visit V3). This was done immediately be-
fore and up to 48 h after the administration of certo-
parin with the following schedule: immediately before
certoparin administration (0 min), at 1 minute, 30 min-
utes, 1 h, 2 h, 3 h, 4 h, 24 h, 48 h after certoparin
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administration. The 48 h sample was taken before appli-
cation of certoparin for the next dialysis session.
In a second subgroup of 36 patients (referred to as
PK-B; introduced after the amendment), additional phar-
macokinetic assessments were performed after 8 weeks
(visit V4). This subgroup included a target number of 6
patients for each of the following bolus doses of
3,000 IU, 3,600 IU or 4,200 IU prior to dialysis, 6
patients with a bolus of 3,000 IU plus an infusion of
600 IU/h up to 1 h before the end of the dialysis session,
6 patients with a bolus of 3,600 IU plus an infusion of
600 IU/h up to 1 h before the end of the dialysis session,
and 6 patients who underwent hemodiafiltration. For
PK-B samples were obtained immediately before certo-
parin administration (0 min), and at 2 h, the end of the
dialysis session and at 48 h (at the following dialysis ses-
sion respectively).
PK samples were collected from the fistula. In
patients with a catheter, blood samples were taken by
venipuncture. All PK samples were processed and kept
frozen at -20°C or less and transferred to the central
laboratory. Anti-Xa activity was measured by hydrolysis
of a chromogenic peptide substrate [18] using certo-
parin to obtain the calibration curve [14]. The PK para-
meters for PK-A were determined in plasma using
non-compartmental methods.
Prothrombin fragment F1/2 (Dade Behring, Germany,
normal values below 230 pmol/l), thrombin-antithrombin
complex (TAT, Dade Behring, Germany, normal values
below 4.2 μg/l)), and D-Dimer (Technoclone, Austria, nor-
mal values below 250 ng/ml) were determined using a
microplate reader (Dynatech, Germany).
Dialyser redness
Clotting of the dialysis filter at week 8 was also assessed by
a specialized central lab (eXcorLab GmbH, Obernburg,
Germany). For this assessment, the filters were flushed with
1 l of saline and stored at 2-8°C before shipment to the spe-
cialized central lab. Redness of the dialysers was quantified
by taking four photographs of each filter (at 0°, 90°, 180°,
270°) and analysed as the mean percentage of the clotted
transversal filter (clotted : total area) by the image analysis
software Image Pro plus, version 6.3 (Media Cybernetics,
Inc., USA). The blue filter of the software was used to en-
hance redness and the flatten filter was enabled to reduce
noise. The distinction between red and white areas was cor-
rected manually using the intensity histogram and by com-
paring the red colour image generated on the screen with
the real area of interest on the spread fibre bundle.
Statistics
This study assessed the feasibility of certoparin as an
alternative treatment option with respect to complica-
tions. Based on clinical experience, the percentage of
unsatisfactory dialysis results was estimated to be in be-
tween 0 and 5% [17,19-21]. It was determined that at a
sample size of 100 patients an observed 1% incidence
would have a 95% CI with a width of 4% (-1 to 3%). At
an observed rate of 3% the width would be 6.6% (-0.3 to
6.3%) and at 5% the width would be 8.6% (0.7 to 9.3%).
This precision was regarded adequate for the purpose of
this trial. An additional 10 patients were allowed to cor-
rect for the broader population (hemofiltration/hemo-
diafiltration) defined in the amendment. Therefore, the
total sample size was 110 patients.
Results
Study population
A total of 120 patients were screened for their eligibility
(Figure 1). Of these, 109 patients were treated with at
least 1 dose of certoparin and made up the safety popu-
lation. 106 patients (97.2% of 109) were available for effi-
cacy analyses (ITT-Population). 95 patients completed
the study per protocol (87.2% of 109). Table 2 displays
patient characteristics of the safety population.
Dosing of certoparin
Certoparin was started at 3,000 IU and uptitrated until a
satisfactory result was obtained. At the final visit 68.9%
of patients received certoparin as a bolus, the majority at
a dose of 3,000 IU (34.0%) and 3,600 IU (22.6%)
(Table 3). Only 4 patients (3.8%) needed a dose below
3,000 IU. Body weight, haemoglobin or the prior UFH
dose were not predictive of the required certoparin dose
with correlation coefficients R2 of 0.1408, 0.0457 and
0.0068, respectively.
Efficacy endpoints
The primary endpoint, which was the percentage of un-
satisfactory dialysis results as per investigator judgement
at the 8 week visit due to clotting or bleeding, was met
in 2 patients of the ITT population (2/106 patients,
1.9%; 95%CI 0.23%–6.65%) and the per protocol popula-
tion (2/95 patients; 2.1%), none of these due to major
Figure 1 Patient flow.
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bleeding. Clotting in the blood lines and bubble catcher
was considered to be moderate to severe in these 2
patients. A total of 3 patients (2.8%) had moderate clot-
ting (redness overall or several [≥ 3] small or few large
[≥2 mm] red fibre bundles) of the dialysis filter at week
8 (Figure 2). A mean of 15.7 ± 14.3% of the dialysis fil-
ters’ visual surface area was showing redness at 8 weeks.
The time to a first and finally satisfactory dialysis
showed an exponential increase with time and demon-
strates that about 50% of patients achieved a satisfactory
dialysis results within the first 2–3 dialysis treatments
(Figure 3).
Antixa activity
In the PK-A subgroup (12 patients), aXa activity
was determined at baseline and at the 4 week follow-up
(Figure 4). Peak activity was 0.69 (95%CI 0.57–0.83) aXa
IU/ml at minute 1. At 24 and 48 h, aXa activity was low
(0.01–0.02) with a number of patients below the detec-
tion limit. Logarithmic transformation resulted in an al-
most linear kinetic (except for the activity determined at
1 min; plot not shown).
In the PK-B subgroup (36 patients different from
PK-A), aXa activity was monitored at the 8 week visit
and results grouped by certoparin dose and dialysis
technique used (hemodiafiltration) (Figure 5). The
results demonstrate larger confidence intervals (vs. the
PK-A group), no sign of certoparin accumulation, a
low dose dependency and comparable levels with
hemodiafiltration.
Results in the PK-A and PK-B subgroups were rather
consistent despite differences in centres involved and
the time frame monitored (8 vs. 4 weeks). At baseline
(n = 12; PK-A; median dose 3000 IU, range ±0), at week
4 (n = 12, PK-A; median dose 3000 IU, range 2400–
6000) and at week 8 (n = 36; PK-B; median dose 3000 IU,
range 2400–6600), median plasma aXa levels 2 h after
administration were 0.24, 0.33 and 0.38 aXa IU/ml. C48h
was 0.01 aXa IU at all visits (below detection limit in
50%, 66.7% and 82.4% of patients).
Coagulation markers
Prothrombin fragment F1 + 2, thrombin-antithrombin
complex (TAT) and D-Dimer (Figure 6) showed that the
activation of coagulation was also present with the use
of certoparin, although the increase between pre- and
post-dialysis in most of these parameters was almost
halved at week 4.
Bleeding complications and adverse events
In 3.0% during 2724 dialyses, prolonged fistula compres-
sion times were reported which corresponded to 45




Mean± SD [years] 66.3 ± 14.7
Median (range) [years] 71 (26-90)
≥ 65 years (n, %) 66 (60.6)
Male gender (%) 63 (57.8)
Weight
Mean± SD [kg] 82.5 ± 18.3
Median (range) [kg] 81.1 (41-151.6)
Dialysis technique
Hemodialysis (n, %) 99 (90.8)
Hemodiafiltration (n, %) 10 (9.2)
Vascular access
Arteriovenous fistula (%) 100 (91.7)
Permanent dialysis catheter (%) 9 (8.3)
Exposure to certoparin
Mean± SD [days] 61.1 ± 33.9
Median (range) [days] 57 (3-397)
Dialyses
Mean± SD [dialyses] 25.0 ± 4.2
Median (range) [dialyses] 25 (2-32)
SD, standard deviation.
Table 3 Distribution of doses at the final dialysis (visit
4/week 8) of the ITT-Population
Total dose
(IU)
Patients with a single
initial bolus
Pts with initial bolus
and infusion
Bolus n (%) Bolus/Infusion n (%)
1200 1200 1 (0.9)
2400 2400 3 (2.8)
3000 3000 36 (34.0)
3600 3600 24 (22.6)
4200 4200 8 (7.5)
4800 3000/1800 1 (0.9)
4950 3000/1950 1 (0.9)
5100 3000/2100 5 (4.7)
5250 3000/2250 2 (1.9)
5400 3000/2400 11 (10.4)
5550 3600/1950 1 (0.9)
5700 3600/2100 2 (1.9)
6000 6000* 1 (0.9) 3000/3000 1 (0.9)
3600/2400 3 (2.8)
6600 4200/2400 6 (5.7)
P
73 (68.9) 33 (31.1)
IU, International Units, ITT, intention to treat; * a bolus of 6000 IU was only
allowed during PK-A.
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patients and 83 cases. Eight patients (7.34%) had at least
one episode of minor bleeding (total cases 11) but none
experienced major bleeding complications. These were
mouth, gastrointestinal and rectal hemorrhage (1 event
each), epistaxis (3 events), hematoma (2 events), arterio-
venous fistula site haematoma (2 events) and arterioven-
ous fistula site hemorrhage (1 event).
There were a total number of 270 adverse events (AE)
in 93 out of 109 patients (85.3%); 32 were suspected to
be drug related. Of 10 adverse events which were con-
sidered to be serious, none was suspected to be related
to the use of certoparin: one of these patients with a pre-
vious cardiac arrest (after 3 study weeks) died. Other
SAEs were renal transplantation (3 patients, considered
because of hospitalization), angina pectoris, atrial
fibrillation, atrial flutter, gastrointestinal haemorrhage,
chest pain, fracture, injury, hypoglycaemia, necrosis of
an extremity and peripheral arterial occlusive disease.
Discussion
The low molecular weight heparin certoparin appears to
be effective and safe for anticoagulation of patients on
maintenance hemodialysis based on the results of this
multicenter, open-label and prospective but non-
controlled trial. The following findings are noteworthy:
1) a satisfactory dialysis result was achieved in 98% of
patients with no bleeding complications requiring pre-
mature interruption of the hemodialysis session or major
bleeding; 2) the majority of patients needed a bolus dose
of 3,000 or 3,600 IU certoparin only which resulted in a
satisfactory dialysis result within 2-3 sessions suggesting
a simple dosing regimen; 3) there was no need for
adjusting the certoparin dose based on body weight; 4)
there was no sign of certoparin accumulation even at
higher doses; 5) in only 3% of dialyses, prolonged fistula
compression times were observed.
Efficacy and safety
From a clinical perspective, a successful dialysis session
is characterized by the absence of clotting or major
bleeding as well as stable dosing during long-term use.
However, there is no established margin for an accept-
able rate of complications against which the rate
observed in this study could be compared. Previous
work published by Schrader et al. reported thrombosis
rates of the extracorporeal circuit of 1.33% for UFH and
1.59% for dalteparin [19]. Saltissi et al. observed that
Figure 2 Clotting of the lines, the bubble catcher and the dialyser at baseline (V2) and after 8 weeks (V4) (results given as % of the ITT
population).
Figure 3 Proportion of patients with a satisfactory dialysis
result (%).
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3.06% of dialyses with UFH and 1.53% of dialyses with
enoxaparin showed clotting (5 or more on a 10 point
scale), severe bleeding events were infrequent with inci-
dence rates of about 0 or 0.1% [20]. Bramham et al.
reported thrombosed circuits in 2.2% of UFH and 0.7%
of tinzaparin treated patients with major bleeding events
between 0 and 0.26% [21]. Finally, the meta-analysis
published by Lim et al. revealed that about 10-11% of
patients had any bleeding complications during dialysis
[17]. The only case of major bleeding they reported was
a patient that had access site bleeding after hemodialysis
with tinzaparin; however, the patient’s activated partial
Figure 4 Pharmacokinetic evaluation (PK-A population; n = 12) at baseline (V2) and 4 weeks (V3). The first sample was obtained after 1
minute, resulting in a high peak compared to other studies in which first samples were obtained later. Legend: values at 24 and 48 h not
displayed (0.01-0.02). In a number of patients these values were below the detection limit of the assay. Means are displayed in red and 95%
confidence intervals in blue.
Figure 5 Pharmacokinetic evaluation (PK-B population; n = 36) at week 8 (V4). Legend: HDF, haemodiafiltration; HDF patients received
median dose of 5400 IU.
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thromboplastin time was elevated and the investi-
gators concluded that the patient accidentally received
additional UFH [21]. The incidence of circuit throm-
boses in this meta-analysis was 2.2% with LMWH and
1.9% with UFH [17]. Against this background, it
appeared reasonable to aim at determining the propor-
tion of patients with complications during dialysis
defined as the presence of clotting or bleeding using a
straightforward, non-controlled design. With an inci-
dence of 1.9% (ITT, 2.1% PP) and no major bleeding
reported and a confidence interval of 0.23-6.65%, we
were thus able to confirm previously reported rates for
other low molecular weight heparins [19,20,22].
Another matter of practical concern is prolonged fis-
tula compression times with the use of heparins. Most
prior studies reporting this variable documented be-
tween 5 and 13 minutes of fistula compression to be ne-
cessary with either LMWH or UFH [17]. Differences
between both treatment options were either negligible
or in favour of the LMWH (shorter compression)
[23-25]. In our study, 45 patients (41.3%) had prolonged
fistula compression times with a total of 83 cases (3.0%
during 2724 dialyses). This appears reasonably low from
a clinical perspective, but, unfortunately, the degree of
“prolongation” was not predefined because of the high
clinical variability and left up to the treating physician
potentially resulting in overestimation of this endpoint.
Dosing of certoparin
The majority of patients in our study needed a bolus
dose of 3,000 or 3,600 IU certoparin, which resulted in a
satisfactory dialysis result within 2-3 sessions. Overall
68.9% of patients received a bolus up to 4,200 IU only
and the remaining patients a combination of bolus/infu-
sion. Only 4 patients needed an even lower dose than
3000 IU. This dose reduction was however not enforced
by the study protocol. This is in principal agreement
with the experience made with other LMWHs, for which
a single bolus administration without any heparin prim-
ing is usually sufficient for effective dialysis [21,26,27].
Davenport reported that, due to its long half-life, a bolus
dose of 0.8 mg/kg enoxaparin is usually sufficient for
about 98% of patients [2]. Tinzaparin, which has a
shorter half-life than enoxaparin, requires two injections
in more patients when dialysing more than 4 but less
than 6 h and in the majority of patients dialysing for
more than 6 h [2]. In his most recent review Davenport
reports on the possibility to reduce enoxaparin to
0.4 mg/kg bolus and reduce tinzaparin to single bolus of
1500 IU to be sufficient as anticoagulation for an inter-
mittent hemodialysis, especially in patients with the risk
constellation for bleeding [3].
The standard dose for the initiation of certoparin was
3,000 IU which was uptitrated in case of relevant coagu-
lation. At uptitrated doses of certoparin, the coagulation
system was found to be still activated, although the in-
crease in prothrombin fragment F1 + 2, thrombin-
antithrombin complex (TAT) and D-Dimer was almost
halved at week 4. These numbers are well comparable
with data published by Milburn et al. who measured
TAT and D-Dimer in 55 patients undergoing
hemodialysis receiving UFH [28]. The elevated TAT
values 31.07 μg/ml during dialysis at baseline were only
half as high at visit 4 (14.90 μg/ml). The differences for
D-Dimer were similar (130.59 vs. 87.23 μg/l). In a study
by Sagedal et al. using dalteparin for hemodialysis in 12
patients, a number of coagulation parameters were
determined [29]. TAT, prothrombin fragment F1 + 2,
antithrombin (coagulation), plasmin-antiplasmin com-
plex (fibrinolysis) and β-thromboglobulin (platelet acti-
vation) were elevated at baseline to the same extent as
in our study at baseline. However, no repeated measure-
ments during long-term dialysis were presented.
Anti-xa activity
In routine clinical practice, anti-Xa activitiy is not usu-
ally monitored because of practical limitations, but clin-
ical inspection of the dialyser and bubble trap is used
instead to adjust dose. However, its determination allows
assessing the degree of anticoagulation and determining
the pharmacodynamics of anti-Xa activity. In our ana-
lyses, we documented a high initial anti-Xa activity at
minute 1 after the injection which sharply declined
thereafter with activities of about 0.4 IU/ml at 1 h
and < 0.2 IU/ml at 2 hours. This latter concentration is
comparable with current clinical practice recommenda-
tions that use targets between 0.2-0.4 IU/ml, particularly
in patients with increased risk for bleeding [30]. How-
ever, this concentration is lower than recommendations
Figure 6 Coagulation markers (Safety population*). Legend:
*109 patients were available for evaluation at baseline (V2) and 103
patients at week 8 (V4).
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for an anti-Xa activitiy for the initial treatment of throm-
bosis (0.4-0.6 IU/ml) [31]. There was no evidence of an
accumulation in our study even at high doses or with
additional certoparin infusion, which fits with previous
data for UFH, dalteparin, tinzaparin and enoxaparin
[19,32]. The data are consistent with prior data on certo-
parin in therapeutic doses (8.000 IE bid s.c.) [14]. The
area under the curve was 5.588 IU*h/ml which corre-
sponds to 2.096 IU*h/ml referring to the lower dose of
3,000 IU in the present study.
Compared to other LMWHs, certoparin appears to
have a rather fast decline of anti-Xa activity, which is
good from a safety perspective. Guillet et al. reported for
enoxaparin that a single injection of 60 IU/kg led to an
anti-Xa activity higher than 1.2 IU/ml during the first
2 h, and between 0.4 and 1.2 IU during the hours 3 and
4 [20]. After the end of dialysis, anti-Xa activity
remained high 10 hrs (0.4 IU/ml) and 24 hrs (0.1 IU/ml)
after injection. This may suggest an increased risk of
bleeding for a prolonged time period after cessation of
dialysis. In a comparative pharmacokinetic study of dal-
teparin 2,500 IU, enoxaparin 40 U/kg and danaparoide
34 U/kg mean aXa activities were reported 4 hrs post in-
jection with 0.2 IU/ml for dalteparin, 0.38 IU/ml for
enoxaparin and 0.54 IU/ml for danaparoide, respectively
[32]. On the other hand the fast elimination of certo-
parin may explain the more frequent need for an infu-
sion in addition to the initial bolus (31.1%) as opposed
to enoxaparin for example for which a repeated bolus is
necessary in only about 2% of cases [2].
Limitations
The MEMBRANE study results are limited by the fol-
lowing considerations: 1) The MEMBRANE study design
was not controlled with placebo, UFH or any other
LMWH. This may be perceived as a limitation but
appeared justified based on the existing data with other
heparins [17] and the low incidence rate of complica-
tions expected. 2) The study included patients with dif-
ferent residual renal function which may have interfered
with certoparin half-life. 3) The degree of “fistula com-
pression time prolongation” was not predefined. This
was because of the potentially high clinical variability
which was and left up to subjective assessment of the
treating physician.
Conclusions
Certoparin appears to be effective and safe for anticoagu-
lation in patients undergoing maintenance hemodialysis.
Bleeding complications were rare and prolonged fistula
compression necessary in only 3% of dialyses. With a
simple titration scheme with about two thirds of patients
needing a single bolus, certoparin is a valuable alternative
to other existing treatment options whose dosing
regimen is more complicated or requires complex dose
adjustment.
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